FAQ

NC100150

 

Topic mentions per year

Topic mentions per year

1999-2015
051019992015

Related topics

Related topics

1 relation

Broader (1)

ferumoxtran-10

Related mentions per year

Related mentions per year

1990-2018
1990200020102020
NC100150
ferumoxtran-10

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Multicenter phase-II trial of safety and efficacy of NC100150 for steady-state contrast-enhanced peripheral magnetic resonance angiography
The aim of this study was to test the safety and efficacy of NC100150 injection for steady-state contrast-enhanced peripheral MR… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2002
2002
Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan, (NC100150) for MRI of renal perfusion: experimental study in an animal model.
PURPOSE To determine the diagnostic value of a new ultrasmall superparamagnetic iron oxide Clariscan, (NC100150) for the… (More)
Is this relevant?
2001
2001
Pre-clinical results with Clariscanâ„¢ (NC100150 Injection); experience from different disease models
A superparamagnetic nanoparticle (NC100150 Injection) was investigated in two different animal models; renal perfusion in pigs… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2001
2001
First-pass myocardial perfusion MR imaging with outer-volume suppression and the intravascular contrast agent NC100150 injection: preliminary results in eight patients.
The authors evaluated the feasibility of combining single-shot T2-weighted turbo spin-echo magnetic resonance (MR) imaging and… (More)
Is this relevant?
2000
2000
NC100150 Injection, a preparation of optimized iron oxide nanoparticles for positive-contrast MR angiography.
A preparation of monocrystalline iron oxide nanoparticles with an oxidized starch coating, currently in clinical trials (NC100150… (More)
Is this relevant?
2000
2000
Three-dimensional MR imaging of pulmonary vessels and parenchyma with NC100150 injection (Clariscan).
The influence of increasing doses of NC100150 Injection (Clariscantrade mark) and echo times on visualization of pulmonary… (More)
Is this relevant?
1999
1999
Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography.
In this Phase I clinical study, a novel ultrasmall superparamagnetic iron oxide contrast agent, NC100150 Injection (Nycomed… (More)
Is this relevant?
1999
1999
Characterization of t1 relaxation and blood-myocardial contrast enhancement of NC100150 injection in cardiac MRI.
A new ultrasmall superparamagnetic iron oxide (Clariscan; NC100150 Injection) was studied in domestic farm pigs. The T1 effects… (More)
Is this relevant?
1999
1999
Use of the intravascular contrast agent NC100150 injection in spin-echo and gradient-echo imaging of the heart.
This is the first study of the intravascular iron oxide particle contrast agent, NC100150 Injection (Nycomed Imaging AS, Oslo… (More)
  • table I
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1999
1999
First-pass myocardial perfusion imaging and equilibrium signal changes using the intravascular contrast agent NC100150 injection.
In this phase I clinical study, the new ultrasmall superparamagnetic iron oxide contrast agent, NC100150 Injection (Nycomed AS… (More)
Is this relevant?